<DOC>
	<DOCNO>NCT01842308</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose carfilzomib give together melphalan see well work treat patient multiple myeloma stem cell transplant . Carfilzomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , melphalan , work different way stop growth cancer cell , either kill cell stop divide . Giving carfilzomib together melphalan may kill cancer cell .</brief_summary>
	<brief_title>Carfilzomib Melphalan Before Stem Cell Transplant Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) carfilzomib add high dose melphalan part conditioning chemotherapy myeloma . ( Phase I ) II . To determine efficacy combination patient myeloma undergoing stem cell transplantation , define achievement complete response ( CR ) . ( Phase II ) SECONDARY OBJECTIVES : I . To examine toxicity associate addition carfilzomib high dose melphalan patient multiple myeloma ( MM ) . II . To determine progression free rate 1 2 year post registration . TERTIARY OBJECTIVES : I . To determine proportion patient achieve minimal residual disease ( MRD ) negative status . II . To assess HevyLite assay prior treatment . OUTLINE : This phase I , dose-escalation study carfilzomib follow phase II study . CONDITIONING : Patients receive carfilzomib intravenously ( IV ) 30 minute day -6 , -5 , -2 , -1 . Patients also receive melphalan IV 1 hour day -4 -3 . TRANSPLANT : Patients undergo autologous stem cell transplant day 0 . After completion study treatment , patient follow day 30 , day 100 , every 90 day 5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<criteria>Serum creatinine = &lt; 2 mg/dL Absolute neutrophil count &gt; = 1000/uL Platelet count &gt; = 50,000/uL Hemoglobin &gt; = 8.0 g/dL Diagnosis symptomatic MM Measurable disease multiple myeloma time baseline value disease assessment define least one following : Serum monoclonal protein &gt; = 1.0 g/dL &gt; = 200 mg monoclonal protein urine 24 hour electrophoresis Serum immunoglobulin free light chain &gt; =10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio Bone marrow plasma cell &gt; = 30 % NOTE : For patient relapse prior transplant , measurable disease time diagnosis NOTE : For patient disease relapse prior transplant , measurable disease time recent relapse immediately prior transplant ; NOTE : If patient treatment relapse disease prior transplant , patient must measurable disease time relapse prior therapy Patient consider autologous stem cell transplantation full dose melphalan ( 200 mg/m2 ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 Recovered toxicity previous chemotherapy ( excludes grade 1 neurotoxicity hematological toxicity ) Provide inform write consent Ejection fraction &gt; = 45 % Corrected pulmonary diffusion capacity great equal 50 % Forced expiratory volume 1 second ( FEV1 ) &gt; = 50 % Forced vital capacity ( FVC ) &gt; = 50 % Negative pregnancy test perform = &lt; 7 day prior registration , woman childbearing potential Willing return Mayo Clinic Rochester , Mayo Clinic Arizona , Mayo Clinic Florida , Washington University School Medicine treatment Note : During Active Monitoring Phase study ( i.e. , active treatment observation ) , participant must willing return consent institution followup Willing provide blood bone marrow sample correlative research purpose Prior autologous allogeneic bone marrow/peripheral blood stem cell transplant More two prior regimen therapy MM Myocardial infarction within 6 month prior enrollment , New York Heart Association ( NYHA ) class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality ; NOTE : Prior study entry , electrocardiogram ( ECG ) abnormality screen document investigator medically relevant Seroreactivity human immunodeficiency virus ( HIV ) , human Tlymphotropic virus ( HTLV ) I II , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) Other active malignancy &lt; 2 year prior registration ; EXCEPTIONS : Nonmelanotic skin cancer carcinomainsitu cervix ; NOTE : If history prior malignancy , must receive specific treatment cancer Any following : Pregnant woman woman reproductive capability unwilling use effective contraception Nursing woman Men unwilling use condom ( even undergone prior vasectomy ) intercourse woman , take drug 28 day stop treatment Other comorbidity , would interfere patient 's ability participate trial , e.g . uncontrolled infection , uncompensated lung disease Concurrent chemotherapy , radiotherapy , ancillary therapy consider investigational ; NOTE : Bisphosphonates consider supportive care rather therapy , thus allow protocol treatment Known allergies component investigational treatment regimen require ancillary treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>